Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced results from its Phase II study of vaginally-administered lidocaine, which the Company is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE